VVOS Extends Financing Deal
Vivos Therapeutics extends Streeterville financing agreement through August 31, reaffirming plan to convert up to $4.5M debt into stock
Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS ), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it has entered into an extension of its previously announced strategic financing agreement with Streeterville Capital, LLC (“Streeterville”). 5 million of its outstanding debt into a combination of perpetual, non-convertible preferred stock and shares of common stock of the Company.
The extension follows the Company’s determination that the original agreement provided too short a timeframe for Vivos to complete its capital-raising requirements.